



The Oncogene Paradigm in Cancer Biology and Therapeutics

Chang Moo*

Department of Toxicology, Sun Yat-sen University, Guangzhou, China

DESCRIPTON

Oncogenes are mutated or overexpressed versions of normal cellular genes known as proto-oncogenes, which play a key role in regulating cell growth, differentiation, and survival. When these genes undergo alterations, they can drive the uncontrolled cellular proliferation that is characteristic of cancer. The transformation of proto-oncogenes into oncogenes is a critical step in the multistep process of carcinogenesis and represents a fundamental concept in modern cancer biology [1].

The activation of oncogenes can occur through various mechanisms, including point mutations, chromosomal translocations, gene amplification, and insertional mutagenesis. One of the earliest discovered and most studied oncogenes is *RAS*, a gene family involved in signal transduction pathways that control cell growth and survival [2]. Mutations in *RAS* genes (*HRAS*, *KRAS*, and *NRAS*) lead to constitutive activation of signaling pathways such as *MAPK* and *PI3K/AKT*, contributing to malignant transformation. *KRAS* mutations, for instance, are prevalent in pancreatic, colorectal, and lung cancers and are often associated with poor prognosis.

Chromosomal translocations represent another significant mechanism for oncogene activation. The Philadelphia chromosome, resulting from a translocation between chromosomes 9 and 22, creates the *BCR-ABL* fusion gene, which encodes a constitutively active tyrosine kinase driving Chronic Myeloid Leukemia (CML). Targeted therapies like imatinib, which inhibit *BCR-ABL*, have revolutionized the treatment of CML, highlighting the therapeutic potential of understanding oncogene biology. Similarly, the *MYC* gene, often activated by translocations in Burkitt lymphoma, encodes a transcription factor that regulates a wide array of genes involved in cell cycle progression and metabolism [3-6].

Gene amplification can also lead to oncogene overexpression and tumor development. *HER2/neu* is a well-known example, amplified in approximately 20%-30% of breast cancers. The overexpression of *HER2* leads to excessive signaling through receptor tyrosine kinase pathways, promoting cell proliferation

and resistance to apoptosis. The development of *HER2*-targeted therapies such as trastuzumab has significantly improved outcomes in *HER2*-positive breast cancer patients, further supporting the role of oncogenes as therapeutic targets [7-9].

Beyond these classical oncogenes, advances in next-generation sequencing have uncovered a broader landscape of oncogenic drivers. Alterations in genes such as *BRAF*, *EGFR*, *ALK*, and *PIK3CA* are now recognized in various solid tumors, and many of these alterations can be targeted with specific inhibitors. For example, *BRAF V600E* mutations are common in melanoma and have led to the development of effective *BRAF* and *MEK* inhibitors that prolong survival in affected patients [10]. *EGFR* mutations, prevalent in non-small cell lung cancer, are responsive to tyrosine kinase inhibitors such as erlotinib and osimertinib, further demonstrating the clinical significance of oncogenes in personalized medicine.

In conclusion, oncogenes play a central role in the initiation and progression of cancer. Understanding their molecular mechanisms has not only deepened our knowledge of carcinogenesis but also paved the way for targeted therapeutic interventions. Continued research into the functions, interactions, and vulnerabilities of oncogenes remains essential for advancing cancer diagnostics and developing more effective, personalized treatment strategies. The integration of genomic data with clinical decision-making holds promise for transforming oncogene research into tangible benefits for cancer patients worldwide.

REFERENCES

1. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A Review. *JAMA Oncol.* 2016;2(10):1346-53.
2. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. *Cancer Treat Rev.* 2016;44:51-60.
3. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell.* 2015;27(4):450-61.

Correspondence to: Chang Moo, Department of Toxicology, Sun Yat-sen University, Guangzhou, China, E-mail: chang@moo34354511.cn

Received: 30-Apr-2025, Manuscript No. JCM-25-29379; **Editor assigned:** 02-May-2025, PreQC No. JCM-25-29379; **Reviewed:** 16-May-2025, QC No. JCM-25-29379; **Revised:** 23-May-2025, Manuscript No. JCM-25-29379; **Published:** 30-May-2025, DOI: 10.35248/2157-2518.25.S50.005

Citation: Moo C (2025). The Oncogene Paradigm in Cancer Biology and Therapeutics. *J Carcinog Mutagen.* S50:005.

Copyright: © 2025 Moo C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

4. Rizvi NA, Hellmann MD, Snyder A. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015;348(6230):124-128.
5. Robert C, Long GV, Brady B. Nivolumab in previously untreated melanoma without BRAF mutation. *N Eng J Med*. 2015;372(4):320-30.
6. Le DT, Uram JN, Wang H. PD-1 blockade in tumors with mismatch-repair deficiency. *N Eng J Med*. 2015;372(26):2509-2520.
7. Berghoff AS, Fuchs E, Ricken G. Density of tumor-infiltrating lymphocytes correlates with the extent of brain edema and overall survival time in patients with brain metastases. *Oncoimmunology*. 2016;5(1):e1057388.
8. McGranahan N, Furness AJ, Rosenthal R. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science*. 2016;351(6280):1463-1469.
9. Jin Y, Dong H, Xia L. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. *J Thorac Oncol*. 2019;14(8):1378-89.
10. Li H, Bullock K, Gurjao C. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nat Commun*. 2019;10(1):1-6.